Combination treatment for advanced colorectal cancer that resisted standard therapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This clinical trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to standard anti-EGFR treatments. The goal is to see if this combination can shrink tumors or slow the cancer down.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have colorectal cancer that cannot be removed with surgery or has spread to other parts of the body.
- Your cancer has certain gene patterns (no KRAS, NRAS, BRAF V600E mutations) — your doctor can check this.
- You have been previously treated with an anti-EGFR drug (like cetuximab or panitumumab) and your cancer stayed stable for at least 16 weeks before it started growing again.
- You must have a good performance status (able to care for yourself and be out of bed most of the day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of three drugs (cetuximab, envolimab, and a chemo called mFOLFOX6) for people with advanced colorectal cancer that has not been treated yet. The goal is to see if this combination is safe and works better than standard treatments.
This trial tests whether the drug ulixertinib, combined with cetuximab (and sometimes encorafenib), can help people with advanced or metastatic colorectal cancer who have already tried EGFR or BRAF-targeted therapy. It aims to find new treatment options for these patients.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This study tests a new combination of drugs (Envafolimab, Cetuxima-β, and mFOLFOX6) for people with a specific type of advanced colorectal cancer that has not been treated yet. It aims to see if this combination is safe and more effective than standard treatments.
This trial tests a new drug combination for people with a specific type of advanced colorectal cancer that has not responded to earlier treatments. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs for people with advanced colorectal cancer that has not responded to standard treatments. The drugs may help your immune system fight the cancer and block its growth.
Hear when a new Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.